Effect on HPV vaccination in Japan resulting from news report of adverse events and suspension of governmental recommendation for HPV vaccination

详细信息    查看全文

• 作者：Akiko Morimoto ; Yutaka Ueda…
• 关键词：HPV vaccine ; Adverse events ; Media reports ; Governmental suspension of vaccination ; Japan
• 刊名：International Journal of Clinical Oncology
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：20
• 期：3
• 页码：549-555
• 全文大小：359 KB
• 参考文献：1.Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69-0PubMed View Article
  2.Japanese Ministry of Health, Labour and Welfare. Vital Statistics in Japan, tabulated by Center for Cancer Control and Information Services, National Cancer Center, Japan May 12, 2012. Available via DIALOG. http://?ganjoho.?jp/?pro/?statistics/?en/?table_?download.?html Accessed April 2014
  3.Munoz N, Bosch FX, Castellsague X et al (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111:278-85PubMed View Article
  4.Smith JS, Lindsay L, Hoots B et al (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121:621-32PubMed View Article
  5.Li N, Franceschi S, Howell-Jones R et al (2011) Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 128:927-35PubMed View Article
  6.Miura S, Matsumoto K, Oki A et al (2006) Do we need a different strategy for HPV screening and vaccination in East Asia? Int J Cancer 119:2713-715PubMed View Article
  7.Jacobs MV, Walboomers JM, Snijders PJ et al (2000) Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 87:221-27PubMed View Article
  8.Clifford GM, Gallus S, Herrero R et al (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366:991-98PubMed View Article
  9.Franceschi S, Herrero R, Clifford GM et al (2006) Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 119:2677-684PubMed View Article
  10.de Sanjose S, Quint WG, Alemany L et al (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11:1048-056PubMed View Article
  11.Onuki M, Matsumoto K, Satoh T et al (2009) Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer. Cancer Sci 100:1312-316PubMed View Article
  12.Gilmour S, Kanda M, Kusumi E et al (2013) HPV vaccination programme in Japan. Lancet 382:768PubMed View Article
  13.The Global Advisory Committee on Vaccine Safety (GACVS). GACVS Safety update on HPV vaccines. 13 June 2013. Available via DIALOG. http://?www.?who.?int/?vaccine_?safety/?committee/?topics/?hpv/-30619HPV_?VaccineGACVSstat?ement.?pdf Accessed April 2014
  14.The Internaional Federation of Gynecology and Obstetrics (FIGO). FIGO statement on HPV vaccination safety. 2 Aug 2013. Available via DIALOG. http://?www.?figo.?org/?files/?figo-corp/?Statement%20?on%20?Safety%20?of%20?HPV%20?vaccination%20-%20?FINAL%20-%20?AUGUST%20-013.?pdf Accessed April 2014
  15.Darden PM, Thompson DM, Roberts JR et al (2013) Reasons for not vaccinating adolescents: national immunization survey of teens, 2008-010. Pediatrics 131:645-51PubMed View Article
  16.Wong MC, Lee A, Ngai KL et al (2013) Knowledge, attitude, practice and barriers on vaccination against human papillomavirus infection: a cross-sectional study among primary care physicians in Hong Kong. PLoS One 8:e71827PubMed Central PubMed View Article
  17.Sotiriadis A, Dagklis T, Siamanta V et al (2012) Increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine. Arch Gynecol Obstet 285:1719-724PubMed View Article
  18.Bodemer N, Muller SM, Okan Y et al (2012) Do the media provide transparent health information? A cross-cultural comparison of public information about the HPV vaccine. Vaccine 30:3747-756PubMed View Article
  19.Holman DM, Benard V, Roland KB et al (2014) Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr 168:76-2PubMed View Article
  20.Kessels SJ, Marshall HS, Watson M et al (2012) Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine 30:3546-556PubMed View Article
  21.Hanley SJ, Yoshioka E, Ito Y et al (2012) Acceptance of and attitudes towards human papillomavirus vaccination in Japanese mothers of adolescent girls. Vaccine 30:5740-747PubMed View Article
  22.Dinh TA, Rosenthal SL, Doan ED et al (2007) Attitudes of mothers in Da Nang, Vietnam toward a human papillomavirus vaccine. J Adolesc Health 40:559-63PubMed View Article
  23.Dempsey AF, Abraham LM, Dalton V et al (2009) Understanding the reasons why mothers do or do not have their adolescent daughters vaccinated against human papillomavirus. Ann Epidemiol 19:531-38PubMed Central PubMed View Article
  24.Japanese Ministry of Hea
• 作者单位：Akiko Morimoto (1) (2)
  Yutaka Ueda (1) (2)
  Tomomi Egawa-Takata (1) (2)
  Asami Yagi (2)
  Yoshito Terai (1) (3)
  Masahide Ohmichi (1) (3)
  Tomoyuki Ichimura (1) (4)
  Toshiyuki Sumi (1) (4)
  Hiromi Murata (1) (5)
  Hideharu Kanzaki (1) (5)
  Hidekatsu Nakai (1) (6)
  Masaki Mandai (1) (6)
  Kiyoshi Yoshino (1) (2)
  Masami Fujita (1) (2)
  Tadashi Kimura (1) (2)
  Junko Saito (1) (7)
  Tomotaka Sobue (8)
  Nobumichi Nishikawa (9)
  Masayuki Sekine (9)
  Takayuki Enomoto (1) (9)
  Yorihiko Horikoshi (1)
  Tetsu Takagi (1)
  
  1. The Obstetrical Gynecological Society of Osaka, 4-4-3 Kawaramachi, Chuo-ku, Osaka, 541-0048, Japan
  2. Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan
  3. Department of Obstetrics and Gynecology, Osaka Medical College Graduate School of Medical Sciences, 2-7 Daigakumachi, Takatsuki, Osaka, 569-8686, Japan
  4. Department of Obstetrics and Gynecology, Osaka City University Graduate School and Faculty of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan
  5. Department of Obstetrics and Gynecology, Kansai Medical University Graduate School of Medicine, 2-3-1 Shin-machi, Hirakata, Osaka, 573-1191, Japan
  6. Department of Obstetrics and Gynecology, Kinki University Graduate School of Medical Sciences, 377-2 Ono- Higashi, Osaka-Sayama, Osaka, 589-8511, Japan
  7. Saito Women’s Clinic, 1-6-1 Miyahara, Yodogawa-ku, Osaka, 532-0003, Japan
  8. Department of Social and Environmental Medicine, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan
  9. Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata, 951-8510, Japan
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Surgical Oncology
  Radiotherapy
  Diagnostic Radiology
  Internal Medicine
  Pathology
  
• 出版者：Springer Japan
• ISSN：1437-7772

文摘

Background Administration of the human papillomavirus (HPV) vaccine decreased dramatically in Japan after extensive news of adverse vaccine events and suspension of the governmental recommendation for the vaccine. In this study, we investigated the knowledge and acceptance of vaccinated adolescents concerning cervical cancer, cancer screening and the HPV vaccine. Furthermore, we analyzed whether and by how much the news affected acceptance of the vaccination. Methods This study was conducted as a part of Osaka Clinical resEArch of HPV vacciNe (OCEAN) study. A questionnaire was distributed to 2,777 study registrants. Results The response rate was 38?%. The recognition rate of the news of the vaccine’s adverse events was 80?%; it was 68?% for awareness of the government’s announcement of the suspension of its recommendation for the vaccine. Among those who had a chance to hear or see the negative news during their vaccination period, 46 (60?%) continued vaccination while knowing of the news, 22 (29?%) discontinued vaccination, and 9 (11?%) continued vaccination without an awareness of the news. Reports of the vaccine’s adverse events were the main reason for not continuing the vaccination series. Those who consulted doctors after hearing the adverse news were significantly more likely to continue their vaccinations than those who did not. Conclusions Our results should help in understanding the need for a strong promotion of vaccine usage and cancer screening after future retraction of the recommendation suspension. This may apply to other countries with an unsatisfactory rate of HPV vaccination due to fears of adverse vaccine events.